1
|
Xu L, Ni N, Gao H, Hu P. MicroRNA-1301-3p promotes the progression of non-small cell lung cancer by targeting Thy-1 and predicts poor prognosis of patients. Oncol Lett 2021; 21:327. [PMID: 33692859 PMCID: PMC7933762 DOI: 10.3892/ol.2021.12589] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Accepted: 11/26/2020] [Indexed: 12/25/2022] Open
Abstract
The role of microRNA (miR)-1301-3p has been investigated in breast cancer and colorectal cancer. Dysregulation of miR-1301-3p expression in non-small cell lung cancer (NSCLC) is speculated to be associated with tumor progression, which was systemically investigated in the present study. Reverse transcription-quantitative PCR analysis was performed to detect miR-1301-3p expression in 124 paired tissue samples and cultured cell lines. The results demonstrated that miR-1301-3p expression was regulated by transfection with miR-1301-3p mimic or inhibitor, and the proliferation, migration and invasion of the transfected cells were assessed via the Cell Counting Kit-8 and Transwell assays. In addition, miR-1301-3p expression was significantly upregulated in NSCLC tissues and cells compared with normal tissues and normal cells, respectively. Notably, upregulated miR-1301-3p expression in NSCLC tissues was significantly associated with the TNM stage, lymph node metastasis and poor prognosis of patients with NSCLC. Furthermore, upregulated miR-1301-3p expression in NSCLC cells promoted cell proliferation, migration and invasion, the effects of which were reversed following miR-1301-3p knockdown. Thy-1 was identified as a direct target of miR-1301-3p, which serves as a tumor promoter in the progression of NSCLC. Taken together, the results of the present study suggest that upregulated miR-1301-3p expression in NSCLC acts as an independent prognostic factor and a tumor promoter by targeting thy-1, thus provides a potential therapeutic target for NSCLC.
Collapse
Affiliation(s)
- Ling Xu
- Department of Respiratory and Critical Care Medicine, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China
| | - Na Ni
- Department of Clinical Medical Laboratory, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China
| | - Haiyang Gao
- Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China
| | - Pengbo Hu
- Department of Emergency, Binzhou Medical University Hospital, Binzhou, Shandong 256600, P.R. China
| |
Collapse
|
2
|
Kitano H, Chung JY, Noh KH, Lee YH, Kim TW, Lee SH, Eo SH, Cho HJ, Choi CH, Inoue S, Hanaoka J, Fukuoka J, Hewitt SM. Synaptonemal complex protein 3 is associated with lymphangiogenesis in non-small cell lung cancer patients with lymph node metastasis. J Transl Med 2017. [PMID: 28623914 PMCID: PMC5473978 DOI: 10.1186/s12967-017-1241-5] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Background The interaction of vascular endothelial growth factor-C (VEGF-C)/VEGF-D/VEGF receptor-3 is considered to be a major driver of lymphangiogenesis, however the mechanism of this process remains unclear. We aimed to investigate the possible lymphangiogenic significance of synaptonemal complex protein 3 (SCP3) in non-small cell lung cancer (NSCLC). Methods The expression of SCP3, VEGF-C, and VEGF-D were measured and examined a correlation between SCP3 and VEGF-C or VEGF-D in various human lung cancer cell lines. Subsequently, we assessed SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D expression in archival tumor tissues from 89 NSCLC patients with lymph node (LN) metastasis by combined immunohistochemistry with quantitative digital image analysis. Results Positive correlations between SCP3 and VEGF-C expression (R2 = 0.743) and VEGF-D expression (R2 = 0.932) were detected in various human lung cancer cell lines. The high expression of SCP3, VEGF-A, VEGF-B, VEGF-C, and VEGF-D were detected in 24 (27.0%), 22 (24.7%), 27 (30.3%), 27 (30.3%), and 24 cases (27.0%), respectively. Notably, SCP3 positively correlated with VEGF-C and VEGF-D expression (for both, P < 0.001) and negatively correlated with VEGF-A and VEGF-B expression (P = 0.029 and P = 0.026, respectively). In multivariate analysis of patients with LN metastasis, SCP3 expression predicted worse overall survival (hazard ratio = 1.86, P = 0.008). Conclusions SCP3 is associated with lymphangiogenesis and provides insight into the SCP3-VEGF-C/VEGF-D axis based cancer therapy strategy. Electronic supplementary material The online version of this article (doi:10.1186/s12967-017-1241-5) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Haruhisa Kitano
- Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.,Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki, 852-8523, Japan
| | - Joon-Yong Chung
- Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA
| | - Kyung Hee Noh
- Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, 136-701, Korea.,Department of Biochemistry & Molecular Biology, Korea University College of Medicine, Seoul, 136-701, Korea
| | - Young-Ho Lee
- Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, 136-701, Korea.,Department of Biochemistry & Molecular Biology, Korea University College of Medicine, Seoul, 136-701, Korea
| | - Tae Woo Kim
- Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, 136-701, Korea.,Department of Biochemistry & Molecular Biology, Korea University College of Medicine, Seoul, 136-701, Korea
| | - Seok Hyung Lee
- Department of Statistics, Korea University, Seoul, 136-701, Korea
| | - Soo-Heang Eo
- Department of Statistics, Korea University, Seoul, 136-701, Korea
| | - Hyung Jun Cho
- Department of Statistics, Korea University, Seoul, 136-701, Korea
| | - Chel Hun Choi
- Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.,Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 135-710, Korea
| | - Shuhei Inoue
- Department of Thoracic Surgery, National Hospital Organization Higashi-Ohmi General Medical Center, Higashi-Oumi, 527-8505, Japan
| | - Jun Hanaoka
- Department of Thoracic Surgery, Shiga University of Medical Science, Otsu, 520-2192, Japan
| | - Junya Fukuoka
- Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, 1-12-4, Sakamoto, Nagasaki, 852-8523, Japan.
| | - Stephen M Hewitt
- Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
| |
Collapse
|